Catharine Johnson, Ph.D.
Interim Chief Business Officer
Dr. Johnson brings a broad range of strategy and corporate development experience to Ribon. An independent consultant since 2012, she has a proven track record of developing and executing corporate strategy, including structuring and negotiating R&D collaborations, acquisitions and licensing agreements for emerging public and venture-backed biotech companies. Prior to consulting, Dr. Johnson was Senior Vice President at aTyr Pharma where she had responsibility for strategic alliances, intellectual property and corporate communications. Previously, she was Vice President, Corporate Development at Momenta Pharmaceuticals, Inc. (MNTA), and an investment Principal at Atlas Venture. Dr. Johnson started her career at Regeneron Pharmaceuticals, where she led business development, new business initiatives, and alliance management.
Dr. Johnson received her Ph.D. in Biochemistry from the Johns Hopkins School of Medicine, and a B.A. in Biophysics from Johns Hopkins University.